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The identification and treatment of mood disorders in children and adolescents has grown over the last
decades. Major depression is one of the most common and debilitating disorders worldwide, imposing
a massive burden to the youth population. Bipolar disorder is being increasingly recognized as having
its roots early in life, and its presentation during childhood and adolescence has been submitted to
extensive research. This review aims to highlight clinical aspects of the current knowledge on mood
disorders in the pediatric population, presenting updated information on epidemiology, diagnostic
procedures, and management strategies. Limitations of available evidence and future directions of
research in the field are also discussed.
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Introduction
Children and adolescents are frequently referred to
psychiatric consultation due to mood complaints. Over
the last decades, there has been an increase in the
recognition of mood disorders among young individuals, a
reflection of the adoption of a developmental perspective
to psychopathology. Longitudinal studies clearly indicate
mood disorders begin early in life, with the majority of first
episodes occurring before adulthood.1 Diagnostic criteria
originally created for the adult population are also
progressively being adapted to capture the specificities
of depressive and maniac episodes in childhood and
adolescence.
This review will focus on the clinical aspects of the two
major diagnostic categories of mood disorders: unipolar
depression and bipolar disorder (BD). Together, they
represent a large burden to young people worldwide,
accounting for more than one-tenth of the global burden
of disease among 10 to 24 year-olds.2 Unipolar depres-
sion is the single most important source of disability
(among all causes) for this age group, corresponding to
8.2% of the disability-adjusted life-years (DALYs); and BD
is ranked fourth, with 3.8% of the DALYs. The impact of
mood disorders on mortality is also marked. Suicide, one
of the leading causes of death among young people, is
associated with depression in at least half of the cases in
adolescence.3 This effect is even more common in the
pediatric bipolar population, with twice the number of
suicide attempts in comparison with individuals with
unipolar depression.4
Depression
Epidemiology
Data on the prevalence of depression in the first years of
life are limited due to the scarcity of appropriate
diagnostic criteria from a developmental point of view.
Studies to date suggest a relatively low occurrence of
depressive episodes in preschool children, affecting
approximately 1 to 2.5% of this population, with no
significant gender differences. Conversely, the estimates
of unipolar depression prevalence up to the end of
adolescence resemble those found in the adult popula-
tion, with 4 to 9% of subjects presenting with a depressive
episode in a 12-month period.5,6
During adolescence, the cumulative risk for the
occurrence of a depressive episode rises from 5 to
20%.3,7 Many factors may explain this increase in the
incidence of depression after puberty. Adolescence is a
crucial developmental period, with the confluence of
biological, psychological, and social changes that can
predispose to the occurrence of mental disorders.8 With
the onset of puberty, there is a rapid physical maturation
process and cognitive growth (with increased capacity for
abstract thinking and generalizations) as well as social
and interpersonal transitions, with changes in the relation-
ship with school, family, and peers.9
One of the most consistent findings in the literature is
the increase in the female/male ratio of individuals
presenting with depression symptoms after puberty.
This discrepancy has been shown not only in referred
samples, but also in population-based studies, and thus is
not likely to occur due to referral bias. Although the
reasons for such difference are not completely under-
stood, it is suggested that hormonal changes have a role
in this phenomenon, acting more in order to increase the
sensitivity to environmental stressors than actually caus-
ing depression per se.
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A major risk factor for the development of depressive
disorders is the high familial loading of depression.10
Different types of investigation, such as adoption, twins or
high-risk studies, corroborate the pivotal role of the
familial component in the etiology of major depression,
probably through gene-environment interactions.11 As for
the adult population, it is believed that the incidence and
recurrence of depressive episodes can be mediated or
moderated by stress factors such as losses, neglect or
abuse, conflicts, and frustrations. However, the effects of
such stressors seem to be mainly conditioned by the way
the child interprets and deals with such adversities.
The median duration of a major depressive episode in
children and adolescents referred to treatment is approxi-
mately 8 months. Although the majority of patients
recover from a first episode, data from clinical and
community studies suggest probabilities of recurrence
from 20 to 60% in the first 2 years after remission,
reaching 70% after 5 years.12
Diagnosis
Even though depressive symptoms can be understood as
a continuum, a diagnostic decision is usually necessary to
define the need for treatment. The American Association
of Child and Adolescent Psychiatry recommends key
screening questions for depression (sad or irritable mood
and anhedonia) in every psychiatric evaluation.13
As with any assessment of children and adolescents, it
is essential to establish a connection and a confidential
relationship with the child or young person, and informa-
tion gathering from the largest number of informants
(child/adolescent, parents, school) is the best strategy to
capture the underlying psychopathology. When there is
need to prioritize one source of information, the literature
seems to suggest that internalizing symptoms in general -
and depressive symptoms particularly - tend to be more
frequently reported by patients in comparison with
caregivers or teachers.
Several lines of evidence point to the importance of
including the family in the understanding, prevention, and
treatment of depressive disorders. Unfortunately, the
currently available diagnostic criteria neglect the impor-
tance of this issue.5 It is recommended that family
assessment takes into account various sociocultural
factors that may influence the presentation, description,
and interpretation of symptoms, focusing not only on
problems, but also including positive aspects, which could
be essential in planning therapeutic approaches.13
Despite the advances achieved with the adoption of
operational classification systems (DSM and ICD), the
difficulties in diagnosing depression in children and
adolescents are higher than those found in older
individuals. This is because the current diagnostic criteria
were developed for the adult population, neglecting many
of the developmental differences between children/
adolescents and adults.
With regard to age differences, the only adaptations of
the DSM-IV-TR for the diagnosis of a major depressive
episode in children are inclusions of irritable mood as one
possible cardinal symptom and of failure to make
expected weight gain as a marker of appetite or weight
change. Furthermore, the DSM-IV-TR also reduces from
2 to 1 year the minimum duration of symptoms required
for characterizing a dysthymic disorder. ICD-10 has no
adjustments related to developmental aspects. Figure 1
shows a suggestion of diagnostic algorithm for depres-
sive episodes.
Even though the current criteria are reasonably
applicable to older adolescents, symptoms such as
excessive guilt, indecisiveness or suicidal ideation have
little applicability among young children. Moreover, even
in adolescents, depression is often less recognized than
in adults, possibly due to factors such as fluctuation of
symptoms, mood reactivity, and strong irritability.3
The presentation of depressive symptoms may vary
according to age groups. Regarding mood changes,
younger children show more temporal variability, making
harder to characterize a mood episode. Adolescents often
conceal their mood changes, frequently presenting as
social isolation. Anhedonia may be manifested as difficulty
in having fun in younger children, but in adolescents it may
be manifested as boredom. The melancholic aspects of
depression (reduction of energy, sleep changes, and
appetite/weight disturbances) are more often seen in
adolescents than in younger individuals. Conversely,
somatic complaints are more common in children, but
can also be found in adolescents.5
Children may have difficulty verbalizing their feelings or
may even deny that they are depressed. Thus, special
attention should be given to observable manifestations
such as changes in sleep patterns, irritability, poor
academic performance, and social withdrawal.13 For the
longitudinal assessment of mood symptoms, it may be
useful to adopt a mood diary or timelines, and use special
dates like birthdays, holidays or school holidays as
anchors. Mood is recorded ranging from very happy to
very sad/angry; in addition, stressful events and possible
treatments should also be registered. The use of time-
lines can be extremely valuable in identifying triggers, in
assessing treatment response, and in the identification of
possible manic or hypomanic episodes (especially in the
differentiation of these in relation to return to euthymia).13
The diagnostic assessment of depressive disorders
can make use of formal procedures such as structured/
semi-structured interviews or rating scales. In addition to
general interviews to assess mental disorders in child-
hood and adolescence (e.g., the Schedule for Affective
Disorders and Schizophrenia for School-Age Children [K-
SADS] and the Development and Well-Being
Assessment [DAWBA]), specific instruments have been
developed for the assessment of depressive symptoms in
children and adolescents. Among the specific scales
more frequently used worldwide and available in Brazilian
versions are the Children’s Depression Rating Scale
(CDRS), the Children’s Depression Inventory (CDI), and
the Kutcher Adolescent Depression Scale (KADS).
Several other problems in childhood and adolescence
may present as depressive symptoms and should always
be considered in the differential diagnosis: bereavement
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or adjustment disorders, oppositional defiant disorder,
substance use disorders, hypothyroidism, anemia, infec-
tions, cancer, and autoimmune diseases. Conversely,
one should remember that depression may end up not
being diagnosed in cases where the chief complaint or
reason for the consultation is physical symptoms, anxiety,
school refusal, decline in academic performance, sub-
stance use or externalizing problems.3
Depending on the clinical context, 40 to 90% of children
and adolescents with depressive disorders have at least
one psychiatric comorbidity, and 50% of young people
have two or more concurrent diagnoses. Among the most
prevalent comorbid diagnoses are anxiety disorders,
followed by disruptive disorders, attention deficit disor-
der/hyperactivity (ADHD), and in adolescents, substance
use disorders.13
One of the areas of greatest uncertainty in the
evaluation of a first depressive episode in a child or
adolescent is whether the episode is part of a unipolar or
a BD. Some risk factors for BD may be useful in the
diagnostic decision, although none of them has sufficient
predictive power to differentiate both disorders: among
them are a strong family history of BD or psychosis and a
history of pharmacologically induced mania or hypoma-
nia.13 Schizophrenia is another rare diagnosis in adoles-
cence, but also a differential diagnosis to be considered,
given that depressive symptoms may precede or accom-
pany psychotic features.3 Another problematic area is the
assessment of depressive symptoms in patients with
intellectual disabilities or mental retardation. Because
these individuals often present with symptoms on multiple
domains, greater efforts are needed for the identification
of mood symptoms in this high-risk population.14
Similarly to what happens to adults, risk assessment is
essential in children and adolescents with depression.
Among young individuals, it is also important to differenti-
ate suicidal from other self-injury behavior, in which the
goal is to alleviate negative feelings. This type of behavior
usually involves repetitive cuts, seeking more relief from
anger, sadness or loneliness than the end of life.
Regarding suicide assessment, recent findings show
that a 4-question screening instrument, the Ask Suicide-
Screening Questions (ASQ), can identify the risk for
suicide in patients presenting to pediatric emergency
departments, with high sensitivity and negative predictive
value. This new screening tool comprises questions
assessing current thoughts of being better off dead,
current wish to die, current suicidal ideation, and past
suicide attempt, with a sensitivity of 96.9% (95%
confidence interval [95%CI] 91.3-99.4) and a specificity
of 87.6% (95%CI 84.0-90.5).15
Treatment
Every treatment plan for depression in children and
adolescents should take into consideration developmental
Figure 1 Diagnostic algorithm for depressive episodes in children and adolescents
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aspects, including psychoeducation, family support,
assessment of comorbid conditions, and risk behaviors.
Moreover, given the nature of chronic and recurrent
depressive disorders, clear objectives should be estab-
lished together with patients and their families not only for
the acute treatment of the current episode, but also for
phases of consolidation and maintenance, monitoring and
preventing new episodes.
Similarly to the management of depression in adults,
mild episodes can be addressed satisfactorily with
psychoeducation and support measures targeting envir-
onmental stressors. A recent meta-analysis suggests the
benefit of physical activity on depressive symptomatology
among children and adolescents, with a small but
significant effect size for the intervention.16 However, for
cases in which the symptoms are more intense, more
specific strategies are often necessary.
In the pediatric population, evidence suggests the
efficacy of pharmacological agents, cognitive behavioral
therapy (CBT) or interpersonal therapy (IPT) - all these
interventions, however, present only intermediate effect
sizes in randomized controlled trials. Given that studies
with children and adolescents usually focus on the
treatment of depressive episodes, the management of
dysthymic or unspecified depressive disorders is fre-
quently extrapolated from the available literature on major
depression.17
The psychotherapeutic techniques with the largest
evidence base in terms of efficacy for the treatment of
depressive episodes in children and adolescents are CBT
and IPT. Psychodynamic approaches have also been
widely employed, despite the absence of clinical trials
evaluating this type of intervention.
Meta-analyses that investigated the efficacy of psy-
chotherapy in the pediatric population (including 35 trials
with children and adolescents18 and 11 trials only with
adolescents19) suggested the efficacy of CBT, but with
effect sizes around 0.3. The largest clinical trial for
adolescents with depression performed to date
(Treatment of Adolescent Depression Study, TADS)
randomized 439 individuals to one of four options: CBT,
fluoxetine, CBT + fluoxetine combination, or placebo.20 In
this study, however, no significant differences in the
response between CBT and placebo were detected (43
and 35%, respectively). Another large clinical trial
(Treatment of Resistant Depression in Adolescents,
TORDIA, n=334) evaluated strategies for resistant
depression and suggested that adding CBT to antide-
pressants may be beneficial.21 A role played by CBT may
be preventing new episodes, as demonstrated in a clinical
trial that suggested an eight times reduction in the risk of
relapse in the first 6 months.22
A smaller body of evidence also points to the efficacy of
IPT in the treatment of depressive episodes in adoles-
cents. Clinical trials to date have compared IPT to
conventional treatment, with no high quality controlled
studies assessing IPT vs. antidepressants or placebo.17
There is a general idea that IPT is especially beneficial for
adolescents with high levels of interpersonal conflict with
parents, high levels of depressive symptoms, and
comorbid anxiety.23 Family-focused interventions also
have the advantage of approaching critical issues of the
child’s context, emerging as a promising strategy in
recent years, especially in young children.5,24
On the path to define the best treatment option for
depression, the Improving the Mood with Psychoanalytic
and Cognitive Therapies (IMPACT) trial is an ongoing
study that is planned to recruit 540 individuals to compare
effectiveness and define superiority in reducing relapse
among three approaches, combined with the use of
fluoxetine as needed: CBT, short term psychoanalytic
therapy, and specialist clinical care.25
Children and adolescents appear to show a response
pattern different from that observed in adults with respect
to antidepressants - both in terms of efficacy and adverse
effects (Table 1). Nonetheless, except for the use of lower
initial doses to avoid side effects, the use of antidepres-
sants in children and adolescents generally follows the
same doses used in adults.
A meta-analysis that evaluated the use of various
selective serotonin reuptake inhibitors (SSRIs), venlafaxine,
mirtazapine, and nefazodone in 13 randomized trials
including 2,910 participants showed that antidepressants
were effective in treating major depression among children
and adolescents. There was a significant response of 61%
in patients treated with active drug compared with 50%
Table 1 Most used antidepressants to treat unipolar depression in children and adolescents
Medication Dose Side effects
Fluoxetine* 20 to 60 mg/day Fluctuations in appetite, weight changes, nausea, diarrhea, constipation, dry mouth, insomnia,
but also sedation, agitation, tremors, headache, dizziness, sweating, sexual side effects, vivid
dreams, akathisia, disinhibition, bruising and rare bleeding, rare hyponatremia, rare
hypotension.
Escitalopram* 10 to 30 mg/day
Citalopram 20 to 60 mg/day
Fluvoxamine 50 to 300 mg/day
Sertraline 50 to 200 mg/day
Venlafaxine 37.5 to 225 mg/day Headache, nervousness, insomnia, sedation, nausea, diarrhea, decreased appetite, asthenia,
sweating, SIADH, hyponatremia, dose-dependent increase in blood pressure.
Duloxetine 20 to 40 mg/day Nausea, diarrhea, decreased appetite, dry mouth, constipation, insomnia, sedation, dizziness,
sweating, increase in blood pressure (up to 2 mmHg), urinary retention.
Bupropion 3 to 6 mg/kg/day Dry mouth, constipation, nausea, weight loss, anorexia, myalgia, insomnia, dizziness,
headache, agitation, anxiety, tremor, abdominal pain, tinnitus, sweating, rash, hypertension,
rare seizures.
SIADH = syndrome of inappropriate antidiuretic hormone.
* FDA-approved for depression treatment in children and adolescents.
Mood disorders in childhood and adolescence S25
Rev Bras Psiquiatr. 2013;35(Suppl 1)
among those who received placebo (number needed to
treat [NNT] = 10). Specific data for fluoxetine suggest a NNT
= 5, which is possibly associated with a greater half-life of
the drug (smaller effect in cases of poor adherence) and a
better design of the studies evaluating this drug.23 An
analysis of the 10 studies cited in the meta-analysis for
which results grouped according to age were available
found that the response to antidepressant treatment was
significant for adolescents (62 vs. 49%), but did not reach
statistical significance among children (65 vs. 58%) -
possibly due to the high placebo response in this age
group. In this meta-analysis, the only antidepressant that
demonstrated efficacy in both children and adolescents was
fluoxetine.26
Currently, the only drugs approved by the FDA for the
treatment of depression in youth are fluoxetine (from age
8) and escitalopram (after 12 years). Other SSRIs used in
clinical practice are sertraline and fluvoxamine, especially
in cases of comorbidity with anxiety disorders, for which
they are approved by the FDA. Paroxetine has limited use
in the younger population, as it demonstrated little
evidence of superiority compared to placebo.17
Other antidepressants studied in the pediatric popula-
tion include venlafaxine, duloxetine, and bupropion - and
the efficacy of the latter two was only suggested in open
studies. In the TORDIA study, venlafaxine showed to be
as effective as other SSRIs in the treatment of refractory
depression, although resulting in more adverse effects,
including suicidality among those with high levels of
suicidal ideation at baseline. Tricyclic antidepressants
have no evidence of effectiveness in treating depression
in children and adolescents, as they were not more
effective than placebo in meta-analyses (Box 1).
Despite the limited number of clinical trials assessing
the efficacy of combined strategies, the use of more than
one treatment intervention is also an option, especially in
cases of moderate to severe depression. The two major
clinical trials in the United States suggest that this
strategy may actually be beneficial. In the TADS, a
combination of CBT + fluoxetine showed a better
response in comparison with other interventions, espe-
cially in terms of reducing suicidal ideation, functional
recovery, and proportion of remissions at week 12.
Similarly, in the TORDIA study, the addition of CBT to
the new medication was associated with a better clinical
response. In the British study Antidepressant and
Psychotherapy Treatment (ADAPT),28 the combination
of CBT + pharmacotherapy was not superior to SSRI
monotherapy at week 28, but the inclusion of patients
with greater severity may have influenced the results (a
more severe subgroup analysis of the TADS also showed
the same result). In the long term, the follow-up of
individuals randomized for monotherapy or combination
therapy suggests that they converge both in the TADS
(36 weeks) and in the TORDIA study (72 weeks). Factors
such as uncontrolled naturalistic follow-up and sponta-
neous remission over time, however, make these results
difficult to interpret.
Giving the variability and uncertainty about the best
treatment available for depressive disorders, the
Cochrane Collaboration has recently released three
meta-analyses investigating the effectiveness and safety
of different depression treatment alternatives. Regarding
the effectiveness of pharmacological, psychological, and
combined treatment, there was limited evidence to
conclude about the superiority of any treatment over
another.29 In respect to the effectiveness and safety of
pharmacological treatment options for child and adoles-
cent depression, the systematic review of the literature
highlighted the high heterogeneity among available
studies, but suggested that fluoxetine should be the
treatment of choice if pharmacological treatment is
considered.30
The same authors also reviewed the available evi-
dence on interventions for preventing relapse and
recurrence of depression in children and adolescents,
Box 1 Use of antidepressants and suicidality in
young individuals
In 2004, the FDA made the decision to include a black
box warning about the risk of suicidality associated
with antidepressant use among individuals under 25
years of age. This initiative was taken after a meta-
analysis involving more than 4,400 children and
adolescents suggest an increased risk of adverse
events of suicidal ideation or behavior during the first
few months of treatment with antidepressants. The risk
of these events was 4% with SSRIs compared with 2%
in the placebo group. More recently, another meta-
analysis including seven studies not evaluated in the
initial review found an increased risk of suicidal
behavior/thoughts with antidepressants (2.5% in
contrast with 1.7% with placebo).26
Based on the fact that for the treatment of
depressive disorders the number needed to treat
(NNT) in this age group is at least 10 and the
number needed to harm (number needed to harm,
NNH) is 112, it was concluded that the benefits
associated with the use of antidepressants outweigh
the potential risks. Moreover, the year after the
inclusion of the warning from the FDA, the number of
prescriptions of SSRIs in the United States fell and
suicide rates increased for the first time after 10 years
of decline or stability.27
In summary, the use of selective serotonin
reuptake inhibitors (SSRIs) in children and
adolescents should be cautious, observing the
emergence of suicidal thoughts or behavior, and
unexpected changes in behavior, such as insomnia,
agitation, and social withdrawal. Knowledge about the
characteristics of such events and an active attitude
seeking to mitigate predisposing factors should be part
of any therapeutic strategy. Suicide-related events
usually happen more early in treatment (3-5 weeks)
and among those who do not respond to drugs, having
as high predictors suicidal ideation at baseline, greater
severity of symptoms, family conflict, and alcohol and/
or drugs use.
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concluding that there is little evidence to establish which
type of treatment approach is most effective, suggesting
that psychological therapies showed encouraging results,
but need replication in larger studies. The pharmacologic
intervention studies showed considerable diversity, but
some studies showed benefit.31
Adopting a developmental perspective for understand-
ing the origins and persistence of mental disorders has
led to the search for preventive strategies to avoid the
incidence of depressive episodes. Studies suggest that
the treatment of mothers with depression is associated
with a lower incidence of psychiatric diagnoses and better
responses to treatment with CBT in children,32 which
reinforces the need for a comprehensive family assess-
ment and interventions directed at caregivers when
needed.
Meta-analyses of preventive strategies suggest that
programs focusing on at-risk individuals (based on factors
such as family history or presence of subsyndromal
symptoms) are more effective than universal strategies.3
Such interventions, generally employing psychoeduca-
tional and cognitive-behavioral techniques, have yet to be
rigorously tested in future studies, which should also
include cost-effectiveness analysis. A recent classroom-
based CBT approach to prevent depressive symptoms in
high-risk adolescents, however, failed to show benefit
with the intervention.33
Bipolar disorder
Epidemiology
The first clues to the investigation of BD in children and
adolescents derived from studies of adults with BD.
Around 0.3 to 0.5% of the adults recall their disorder
onset in childhood (before age 10), and over 60% before
age 18.34,35 An epidemiological study in prepubertal
children conducted in the United States found a pre-
valence estimate of 0.1% of hypomania (BD type II), and
no cases of mania (BD type I) in children aged 9 to 13
years.36 A community-based investigation of mental
disorders in Brazil assessed 1,251 subjects from 7 to
14 years in Taubate´ and did not detect any cases of BD
using the DAWBA.37
A different situation is observed among adolescents. In
a recent large community research, 10,123 adolescents
were evaluated using a modified version of the Composite
International Diagnostic Interview (CIDI). The authors
found that 2.5% of youth met criteria for lifetime BD type
I or II and 1.7%, for mania only.38 No large epidemiological
study assessed adolescents in Brazil to date. Clinical
samples have revealed prevalence estimates ranging from
1.7 to 4.2%.39 In Brazil, a study found 36 subjects with
pediatric BD (PBD; , 15 years old) in a sample of 500
patients from a child and adolescent psychopharmacology
outpatient program.40 These data combined suggest the
prevalence of BD type I and II in children and adolescents
to be between 0.1 to 2.5%.34,38,41
Hereditary factors play an important role in BD etiology,
and BD heritability has been suggested to be 0.56. The
risk of BD in offspring of parents with BD is highly variable
across studies, ranging from 2.8% (Netherlands) to 14-
50% (United States). When family members of children
and adolescents with BD are evaluated, the risk in first-
degree relatives varies between 12 and 35%. In adults,
the rates are around 5 to 10%, suggesting a larger
genetic component in the early-onset form of BD.42-44
In naturalistic studies of BD among children and
adolescents, the recovery rates are high (70 to 100%),
but the recurrence rate in 2 to 5 years is up to 80%.45-47
Moreover, most of the time these patients experienced
subsyndromal and syndromal mood symptomatology and
frequent mood fluctuations, as reported in the Course and
Outcome of Bipolar Youth (COBY, n=263) 2-year follow-
up study.48 This may explain the fact that 80% of children
and adolescents suffering from BD do not reach
functional remission.49
The functional impairment of patients with PBD is
remarkable. The disorder interferes with emotional,
cognitive, and social development across the lifecycle.
Indeed, these patients have a high risk for substance
abuse, legal problems and suicide attempts.50-53
The main factors associated with poor BD prognosis
are the following: earlier age of onset, duration of
symptoms, rapid cycling, mixed episodes, psychotic
symptoms, comorbidities such as ADHD and anxiety
disorders, low socioeconomic status, negative life events,
presence of psychiatric disorders in the family, absence
of psychotherapy, low adherence to pharmacological
treatment, use of antidepressants and alcohol.45-48,54-56
Diagnosis
It is important to mention that there are no tests to
diagnose BD. Currently, no neuroimaging technique or
neuropsychological test is specific to BD, and they have
only been used for research purposes. The diagnosis is
based on a careful symptom review, and sometimes only
longitudinal follow-up may reveal the symptoms. As with
other diagnoses in child and adolescent psychiatry,
several sources of information are preferred.
BD is present when significant, persistent, and impair-
ing changes in mood are observed (mania or hypomania,
and depression).57 Different research groups have been
trying to establish what symptoms are important and their
duration, in an attempt to correctly classify mood changes
in children and adolescents. Youth with BD present more
instability than adults with BD, more mixed and psychotic
symptoms, and worse outcomes. Major focuses of
controversies in PBD are irritability, which may be present
in other psychopathologic entities, and the duration of
symptoms.58 Table 2 presents the criteria proposed by
different research groups. From a clinical perspective,
nonetheless, it is recommended that DSM-IV-TR and
ICD-10 operational criteria remain the gold standard until
new data becomes available.
Diagnostic challenges are amplified by the high
proportion of comorbidity with disruptive disorders,
especially ADHD. The presence of comorbidities may
confer worse functional outcome and response to
treatment.60
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Semi-structured interviews, checklists, and symptom
scales may help in the differential diagnosis. The most
commonly used instruments are the K-SADS,61 the Child
Behavior Checklist (CBCL),62 and the Young Mania
Rating Scale (YMRS).63 All of them have been validated
in Brazil, and, as mentioned before, do not provide a
definitive diagnosis, but may suggest comorbidities, and
allow symptom follow-up.64-66
Treatment
Pharmacological treatment in children and adolescents
with BD is mandatory not only in the acute phase that
may involve crisis stabilization for psychosis, suicidal
behavior or agitation, but also to prevent relapses and
recurrences. The mainstay for the management of BD is
the use of medication along with enhancement of social
skills and family support. The major goal is to achieve
mood stabilization so that the patients can achieve their
optimal emotional, cognitive, and social development.67
For a review, see Peruzzolo et al.68
Even though short-term clinical trials have been
increasing in number, current algorithms lack evidence-
based data for many facets of PBD, such as bipolar
depression, or absence of response to other agents.
Moreover, the full impact of long-term use of the
medications used to treat these children and adolescents
has not been determined. Table 3 displays the most used
mood stabilizers and atypical antipsychotics to treat BD in
children and adolescents in clinical practice and their
most common side effects.
One of the most important clinical trials in PBD is the
Treatment of Early Age Mania (TEAM) study that
evaluated 279 children and adolescents with DSM-IV
BD type I. Patients were randomly assigned to receive
lithium, divalproex sodium or risperidone for 8 weeks.
Risperidone presented higher response rates in compar-
ison with lithium (68.5 vs. 35.6%) and divalproex sodium
Table 2 Criteria adopted to diagnose BD in children and adolescents by main research groups
Research center Criteria adopted
Washington University School of
Medicine59
- DSM-IV-TR + requirement of at least one cardinal manic symptom (elation and/or grandiosity);
irritability is not considered alone due to its low specificity.
- Episode: whole duration of illness; cycles: mood changes lasting a minimum of 4 hours.
Massachusetts General Hospital,
Harvard Medical School49
- DSM-IV-TR.
- When severe irritability is present, there is no need for change in the usual mood pattern.
University of Pittsburgh Medical
Center46
- BD-NOS definition: DSM-IV-TR modified in relation to the number of symptoms; if elation is present
it is required more two symptoms of the DSM-IV-TR item B; and if irritability is present, three
symptoms.
- Duration of symptoms: at least 4 hours/day for 4 days (not necessarily consecutive days).
National Institute of Mental Health
(NIMH)58
- Four different groups to cover the different presentations:
- restricted phenotype (DSM-IV-TR), including cardinal symptoms and duration;
- two intermediate phenotypes: one with hypomania or mania but without fulfilling the duration
criteria (1 to 3 days), and the other without hypomania or mania, but irritability instead;
- broad phenotype named severe mood dysregulation, chronic irritability, marked reactivity to
negative stimuli; and hyperarousal, at least three times a week, for more than 1 year.
BD-NOS = bipolar disorder not otherwise specified.
Table 3 Most used mood stabilizers and atypical antipsychotics to treat BD in children and adolescents
Medication Dose Side effects
Mood stabilizers
Lithium 10 to 30 mg/kg/day Polyuria, polydipsia, diarrhea, nausea, weight gain, acne, hair loss, tremor, ataxia,
thyroid and renal abnormalities (diabetes insipidus), cognitive deficits.
Divalproex sodium 15 to 60 mg/kg/day Sedation, nausea, vomiting, weight gain, tremor, hair loss, thrombocytopenia, liver
toxicity, pancreatitis, polycystic ovary syndrome, increase testosterone.
Carbamazepine 10 to 20 mg/kg/day Sedation, nausea, vomiting, ataxia, dizziness, liver toxicity, Stevens-Johnson
syndrome, spinal cord suppression, hyponatremia.
Oxcarbazepine 8 to 10 mg/kg/day Drowsiness, nausea, vomiting, headache, dizziness, sedation, bone marrow
suppression.
Lamotrigine 25 to 300 mg/day Dizziness, tremor, drowsiness, nausea, headache, skin rash, Stevens-Johnson
syndrome.
Topiramate 25 to 300 mg/day Dizziness, sedation, psychomotor retardation, cognitive change.
Atypical antipsychotics
Risperidone 0.5 to 6 mg/day Weight gain, sedation, increased salivation, gynecomastia, abdominal pain,
nausea, hyperprolactinemia, dyslipidemia and diabetes mellitus.
Olanzapine 5 to 20 mg/day Weight gain, dizziness, sedation, constipation, dry mouth, tachycardia,
dyslipidemia and diabetes mellitus.
Quetiapine 25 to 600 mg/day Drowsiness, sedation, dizziness, weight gain, dry mouth, constipation,
tachycardia, dyslipidemia and diabetes mellitus.
Aripiprazole 2.5 to 45 mg/day Drowsiness, nausea, vomiting, constipation, headache, dizziness.
Ziprasidone 40 to 160 mg/day Activation symptoms, dizziness, sedation, nausea, dry mouth.
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(68.5 vs. 24.0%), but had potentially serious metabolic
effects (increased weight gain, body mass index, and
prolactin level). There were no significant differences
between lithium and divalproex sodium.69
In 2011, a systematic review of randomized controlled
trials published from 1989 to 2010 on the pharmacother-
apy of pediatric mania was published.70 The authors
found 29 open-label and 17 randomized clinical trials of
antimanic agents conducted with 2,666 children and
adolescents with BD. The main conclusions were that the
best results were found in the double-blind studies of
aripiprazole, olanzapine, quetiapine, and risperidone.
Other mood stabilizers (lithium carbonate, divalproex
sodium, and carbamazepine) had modest effects when
used as monotherapy in the treatment of PBD. Negative
findings were reported in controlled clinical trials of
topiramate and oxcarbazepine. In an open-label study,
adjunctive lamotrigine had antidepressant and antimanic
effects in PBD. Additional clinical trials are required to
assess the treatment efficacy for depressive episodes
and for the comorbidity with ADHD, as well as to evaluate
the safety and efficacy of psychotropic drugs in children
younger than 10 years.
Currently, the only drugs approved by the FDA to treat
BD in childhood and adolescence for manic episodes are
risperidone and aripiprazole for children aged 10 years or
older, and lithium for children over 12 years. For acute
mania in BD type I, quetiapine for children older than 10
years and olanzapine for adolescents from 13 years have
been also approved. No medication has been approved
to treat all phases of PBD.71
The medication should be chosen according to
scientific evidence, mood state, presence of psychotic
or suicidal symptoms, aggressiveness, potential side
effects, previous history of patient or parent drug
response and the patients and their families’ prefer-
ence.67 For instance, in a depressive episode, lithium
could be chosen based on studies in adults, and
lamotrigine as an alternative. The adjunctive treatment
with SSRIs or bupropion may be required, but should be
indicated with caution due to the risk of inducing manic
switch. Maintenance time recommended for antidepres-
sants is 8 weeks after depressive symptoms remission.72
Although evidence-based data on the maintenance
treatment for PBD is scarce, it has been recommended
to maintain medication for 12 to 24 consecutive months
after remission. The medication should be discontinued
slowly, at a time of stability in the patient’s life and
carefully monitor for possible signs of instability or
relapse.72
The main objectives of psychotherapy in the treatment
of children and adolescents with BD are understanding
the disease; increasing family engagement; teaching
strategies for solving problems and dealing with symp-
toms; reducing prejudice led by the disease; and
preventing further recurrences.73
The psychosocial interventions that have evidence-
based efficacy are psychoeducation for parents and
children,74 family-focused therapy,75,76 and CBT.77
Psychoeducation aims to teach patients and families
about the disorder and its treatment, especially the
recognition of early signs of relapse. All the other
modalities have a psychoeducational component.
Family-focused therapy has the goals of improving family
coping strategies, problem-solving skills and communica-
tion among family members. CBT focuses on problem-
solving and teaching strategies to deal with harmful or
negative thought patterns and behaviors. Recently, a
brief motivational intervention for preventing weight gain
among youth with BD initiating mood-stabilizing pharma-
cological treatment has been proposed.78
Final considerations
Despite the high burden and global impact of mood
disorders, until recently those conditions were neither
identified nor treated in child and adolescent population.
In the last two decades, an impressive growth in research
on the field has been accomplished. The early accurate
identification and treatment of mood disorders can have
direct and indirect impact on subsequent ages, reducing
disability, costs and even mortality across the lifecycle.
Preventive strategies for high-risk individuals, as well as
cost-effectiveness analyses for better definition of public
policies should be considered priorities in future research.
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